Oncogramme, a new individualized tumor response testing method: application to colon cancer.
Colon cancer is the second leading cause of cancer-related death in industrialized countries. Many anti-cancer researches are consequently performed and individualized tumor response testing (ITRT) methods are now used to individualize patient chemotherapeutic administrations. Then, a new ITRT method, Oncogramme, was developed for colon cancer. Colon tumor fragments from different patients were dissociated and seeded in a defined culture medium. Cell preparation process as well as culture medium allowed high cell viability and a good primary culture success rate. After treatment of isolated tumoral cells by chemotherapeutics alone or in combination, cytotoxicity was determined by cell death assay allowing the Oncogramme establishment, which was validated by statistical analysis. Indeed, significant results were obtained such as different profile for each patient's cells with various drugs, and variability between patient's cells in the response to each drug. Procedure described here to obtain the Oncogramme is a new, fast and technically reliable ITRT method applied to colon cancer. For an individualized cancer treatment use, this test should be further validated by a phase I clinical trial.
Loum
Elodie
E
Oncomedics, Faculté de Médecine, 2 rue du Docteur Marcland, 87027, Limoges, France, e.loum@oncomedics.com.
Giraud
Stephanie
S
Bessette
Barbara
B
Battu
Serge
S
Mathonnet
Muriel
M
Lautrette
Christophe
C
J Clin Oncol. 2007 May 1;25(13):1670-6
17470860
Cancer Res. 1981 May;41(5):1751-6
7214343
J Natl Cancer Inst. 1981 Jun;66(6):981-8
7017216
Tech Coloproctol. 2004 Nov;8 Suppl 1:s167-9
15655611
Clin Cancer Res. 1997 May;3(5):741-7
9815744
Blood. 1990 Dec 1;76(11):2327-36
2257305
Anticancer Drugs. 1998 Jan;9(1):51-7
9491792
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Am J Obstet Gynecol. 2003 Nov;189(5):1301-7
14634558
Cells Tissues Organs. 2007;185(1-3):20-8
17587804
Eur J Cancer. 1997 May;33(6):960-6
9291821
Eur J Cancer. 2010 Mar;46(4):765-81
20116997
Cancer Surv. 1993;16:15-29
8348534
Tumori. 2001 Jan-Feb;87(1 Suppl 1):S85
11300039
Anticancer Res. 1990 Sep-Oct;10(5A):1189-200
2241098
Mol Toxicol. 1989 Oct-Dec;2(4):271-84
2490980
J Clin Oncol. 2004 Jan 15;22(2):229-37
14657227
Anticancer Res. 1998 Sep-Oct;18(5A):3579-83
9858942
J Clin Oncol. 1992 Jun;10(6):896-903
1534121
Gastric Cancer. 2006;9(2):82-7
16767362
Leuk Lymphoma. 2003 May;44(5):783-9
12802914
Cancer Metastasis Rev. 1984;3(3):177-91
6437669